<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928134</url>
  </required_header>
  <id_info>
    <org_study_id>VitK2</org_study_id>
    <nct_id>NCT01928134</nct_id>
  </id_info>
  <brief_title>The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis</brief_title>
  <official_title>The Efficacy of Vitamin K2 on Human Osteoporosis, Blood-vessel Calcification and Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study used the generally recognized as safe (GRAS) grade of Bacillus subtilis natto to
      produce Vitamin K2, Menaquinone-7(MK-7), via fermentation, for functional evaluation. There
      are four major objectives for this study: (1) bioavailability of calcium; (2) evaluation of
      bone density improvement; (3) evaluation of blood-vessel calcification and sclerosis
      improvement; (4) safety evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Serum Calcium</measure>
    <time_frame>at 4 hours after intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine calcium/creatinine ratio</measure>
    <time_frame>at 4 hours after intake</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in serum Parathyroid hormone(PTH)</measure>
    <time_frame>at 4 hour after intake</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vit K2+ Vit D3+ calcium carbonate (CaCO3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vit K2+CaCO3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vit K2+ Vit D3+ calcium carbonate (CaCO3)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vit K2+CaCO3</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and non-pregnant women who are at least 20 years and under 75 years of age; and

          2. Female subjects cannot be pregnant or breast feeding.

          3. Patients who are, in the opinion of the Investigator, able to comply with the
             requirements of the study; and

          4. Patients who have been adequately informed of the nature and risks of the study and
             who have given written informed consent prior to receiving study medication.

        Exclusion Criteria:

          1. Women who are pregnant, as determined by a urine pregnancy test, or breast-feeding.

          2. Presence or history of congestive heart failure (NYHA class III/IV) within the prior
             12 weeks.

          3. Recent myocardial infarction (within the prior 12 weeks).

          4. Unstable angina pectoris.

          5. Known or suspected renal insufficiency defined as creatinine&gt;1.5mg/dl.

          6. Known or suspected hepatic insufficiency defined as abnormal liver function tests
             (GOT/GPT) &gt;3x upper normal limit (i.e., 120 U/l).

          7. Known hypomotility syndrome: (such as hypothyroidism or scleroderma).

          8. Recent major trauma within the prior 12 weeks.

          9. Recent surgery requiring anesthesia including coronary artery bypass graft (within 12
             weeks).

         10. Recent hospitalization (within 12 weeks)

         11. Uncontrolled hypertension (defined as a systolic blood pressure&gt;180mmHg or a diastolic
             blood pressure &gt;105mmHg).

         12. Uncontrolled hyperlipidemia (defined as total cholesterol&gt;240mg/dL or triglyceride
             &gt;200mg/dL).

         13. Uncontrolled diabetes (defined as HbA1c&gt;7%).

         14. Cigarette smoker (&gt;=1/day).

         15. Acute infection requiring current antibiotic therapy.

         16. Current use of anticoagulant medication (e.g., warfarin).

         17. Recent or abrupt change (within 1 month) in usual diet.

         18. Use of an investigational drug (within 30 days prior to enrollment).

         19. Known allergies to the component of study medication

         20. Patients have acute disease, and in the opinion of investigators, are not suitable to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Li Su, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhua Christian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>Shih-Li Su</investigator_full_name>
    <investigator_title>Attending Physician of Section of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Vitamin K2</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>Bioavailability of calcium</keyword>
  <keyword>volunteers</keyword>
  <keyword>Men</keyword>
  <keyword>non-pregnant women</keyword>
  <keyword>twenty years of age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

